SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Jurgis Bekepuris
To: Graham Osborn who wrote (57231)5/2/2016 11:28:25 PM
From: MNTNH1 Recommendation  Read Replies (2) of 78748
 
My impression was that while GILD's treatment is expensive (think I read about $80k), its only slightly higher than its peers ($65k-70+k). And there aren't that many peers doing Hep C. Offhand I know the most recent being MRK which is suing GILD for the "formula" used for the highly profitable Solvadi/Harvoni as well as ABBV which is trying to take away share by negotiations with ESRX.

Slamming GILD for high medicine prices appears to be flimsy versus Martin Schkreli's Turing Pharma type of price increase. Firstly, GILD did not just buy the portfolio and jack prices all day long. They got some basic HepC drugs, bought a firm and researched a delivery thats once a day with higher efficacy within 8 weeks . This compares to the usual 3-4 times daily dosage for other competitors' drugs that extends to 12 weeks medication period.

The threat comes from people like ABBV whos willing to cut prices real low (to offset their disadvantages) in order to gain market share. I think congress wise, too early to tell if they would do anything and it would be many years in the works. Patent wise it expires 2029s if Im not wrong, so heres over a decade to milk this. However, its not terribly cheap. I was also reading their HIV pipeline may be promising, not sure if any truth in it? @Graham?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News